TOKYO--(BUSINESS WIRE)--Sosei Group Corporation (“Sosei”)(TOKYO:4565) confirms the new data from three clinical trials presented by Novartis at the European Respiratory Society (ERS) International Congress, September 6-10, in Munich, Germany. The LANTERN study demonstrated that once-daily Ultibro® Breezhaler® (indacaterol/glycopyrronium bromide) was superior in reducing exacerbations (flare ups) and improving lung function compared to twice-daily Seretide® Accuhaler®* (salmeterol/fluticasone (SFC)), in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD).
Help employers find you! Check out all the jobs and post your resume.
